Albireo Appoints New Members to Board of Directors
– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances...
Pharmaceutical
SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results
Expects cash is sufficient to fund operations for the forward twelve monthsSIOUX FALLS, S.D., Aug. 10, 2022 (GLOBE NEWSWIRE) --...
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
OXNARD, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company,...
Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids
– PGX Technology continues to demonstrate the ability to generate superior novel bioactive delivery systems – Findings from the collaborative...
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines - - In Three of the Four Cell Lines,...
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second...
Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directors
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly...
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022
MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million...
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference...
Rapid Micro Biosystems to Announce Second Quarter 2022 Financial Results on August 12, 2022
LOWELL, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences...
Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine
SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked...
MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS...
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in...
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics,...
Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call
ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,...
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD...
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an...
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00...
TOMI Environmental’s SteraMist Provides Protection Against Monkeypox and Other Pathogens As World Combats Increasing Frequency of Outbreaks
Coronavirus Is Not An Outlier In Interconnected Age of Air Travel and Urbanization; TOMI Environmental Partners With Customers To Provide...